Charles River Laboratories
CRLBusiness Overview
source: coverage-next-full ticker: CRL step: "01" title: Business Overview — Charles River Laboratories created: 2026-05-29
Step 01 — Business Overview
Company Description
Charles River Laboratories International, Inc. (CRL) is the world's largest contract research organization (CRO) specializing in early-stage drug development services. Founded in 1947 by Dr. Henry Foster in Boston, Massachusetts, CRL has grown from a small animal supplier into a vertically integrated research partner serving virtually every major biopharmaceutical company in the world. The company provides outsourced research services across the drug discovery-to-IND continuum — from research model supply to full GLP toxicology studies required for FDA regulatory submissions.
CRL's core value proposition is enabling pharmaceutical, biotechnology, and government/academic clients to outsource drug discovery and preclinical development functions rather than maintaining expensive in-house capabilities. The company serves as a one-stop shop, offering integrated solutions from target identification through IND-enabling studies.
Business Segments
1. Research Models & Services (RMS) — ~25% of Revenue
The legacy anchor of the business, tracing back to the founding. RMS supplies:
- Research Models: Inbred and outbred rodents (mice, rats), rabbits, and non-human primates (NHPs) for biomedical research
- Genetically Modified Models (GMMs): Custom transgenic/knockout mice, CRISPR-engineered models via partnerships (including an alliance with Taconic Biosciences)
- Research Model Services: Insourcing solutions (GEMS — staffing researchers at client sites), research animal diets and bedding
- In Vitro Research Tools: Avian products, biologics testing reagents (particularly Endosafe endotoxin testing)
RMS is the most stable segment, with long customer relationships in academic/government settings. However, margins face pressure from elevated NHP costs (sourcing disruption post-COVID, USDA import restrictions) and declining rodent demand from biotech downturn.
2. Discovery & Safety Assessment (DSA) — ~55% of Revenue
The largest segment by revenue. DSA covers:
- Safety Assessment: GLP (Good Laboratory Practice) toxicology studies — the regulatory backbone for IND submissions. Multi-dose rat/dog studies, carcinogenicity, reproductive toxicology, genetic toxicology
- Drug Discovery Services: Medicinal chemistry, computational chemistry, DMPK (drug metabolism/pharmacokinetics), in vitro pharmacology, lead optimization
- Cellular & Molecular Services: Genomics, proteomics, bioanalytical services
- Regulatory Consulting (Insourcing): Site placements of scientific staff (acquired Citoxlab, BioReliance, and other specialty CROs over years)
DSA is the primary driver of CRL's revenue and profit but is also the most cyclically exposed segment — directly tied to biotech funding cycles and pharma R&D budget trends.
3. Manufacturing Solutions — ~20% of Revenue
Testing and CDMO services for commercial biologic manufacturing:
- Biologics Testing: Endotoxin (Endosafe cartridge-based platform), sterility, microbial identification for QC/QA
- Cell & Gene Therapy (CGT) Testing: Potency assays, raw material testing, viral vector analytics
- CDMO Services: Cell therapy manufacturing, viral vector production (capacity built out 2021–2023, now rationalized)
- Microbial Solutions: Pharma-grade bacteria for bioreagent manufacturing
Manufacturing Solutions is the most resilient segment, serving commercial-stage products on recurring QC/QA testing schedules.
End Markets
| Customer Type | Approx. % Revenue | Notes |
|---|---|---|
| Large Pharma | ~40% | Stable; Pfizer, J&J, AZ, Lilly among top clients |
| Mid Pharma / Specialty | ~20% | Moderate; can be lumpy |
| Biotech (small-cap) | ~35% | Most volatile; drove 2022–2024 downturn |
| Government / Academic | ~5% | NIH, BARDA; stable but not a growth driver |
Geographic Mix (FY2024)
- North America: ~54% of revenue
- Europe: ~38% of revenue
- Asia-Pacific / Other: ~8% of revenue
Customer Concentration
No single customer represents more than 10% of revenue. Top 10 customers collectively ~30–35% of revenue, providing meaningful but not excessive concentration risk.
Employees
Approximately 20,000–22,000 employees globally as of FY2024 (down from ~24,000 at the 2022 peak following restructuring).
Corporate History Highlights
- 1947: Founded by Dr. Henry Foster as a rodent supplier in Boston
- 2000: IPO on NYSE
- 2002–2019: Series of acquisitions building out the DSA platform (Inveresk, Argus, Cerebricon, WIL Research, MPI Research, Merial limited assets)
- 2019: Acquired Citoxlab (European toxicology) for ~$524M
- 2021: Agreed to acquire Cognate BioServices (CGT CDMO) for $875M; merged cell/gene therapy capabilities
- 2022: Sold vaccine research business (SAMDI Tech)
- 2023–2024: Launched "Fit for Purpose" restructuring — eliminated ~3,400 jobs (~13% of workforce), closed/consolidated facilities to reduce fixed cost base
- 2024: Divested CDMO segment (Vigene Biosciences, Eton Biosciences) in portfolio rationalization; exiting cell therapy CDMO
Financial Snapshot
source: coverage-next-full ticker: CRL step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot
Income Statement Summary (FY2022–FY2024)
| Metric | FY2022 | FY2023 | FY2024E |
|---|---|---|---|
| Revenue | $3,946M | $3,872M | ~$3,790M |
| Revenue Growth YoY | +14.1% | (1.9)% | ~(2.1)% |
| Gross Profit | $1,269M | $1,177M | ~$1,110M |
| Gross Margin | 32.2% | 30.4% | ~29.3% |
| Adjusted Operating Income | ~$770M | ~$710M | ~$640M |
| Adjusted Operating Margin | ~19.5% | ~18.3% | ~16.9% |
| GAAP Operating Income | $571M | $423M | ~$330M |
| GAAP Net Income | $385M | $253M | ~$195M |
| Adjusted Net Income | ~$600M | ~$545M | ~$520M |
| GAAP EPS (diluted) | $7.57 | $5.07 | ~$4.00 |
| Adjusted EPS (diluted) | $12.29 | $11.21 | ~$10.55 |
| Adjusted EPS Growth | +9.0% | (8.8)% | ~(5.9)% |
| D&A | ~$200M | ~$200M | ~$195M |
| Adjusted EBITDA | ~$960M | ~$900M | ~$820M |
| Adjusted EBITDA Margin | ~24.3% | ~23.2% | ~21.6% |
Note: "Adjusted" figures exclude amortization of intangibles (~$140–160M/year from acquisitions), restructuring charges, and non-recurring items. FY2024 figures are estimates based on reported Q1–Q3 actuals and Q4 2024 guidance.
Key P&L Observations
Revenue Trajectory
- FY2022 represented the post-COVID peak — exceptional biotech funding drove elevated study demand, particularly in DSA
- FY2023 saw first revenue decline in over a decade as biotech funding collapsed
- FY2024 decline continued, but rate of decline moderated; sequential improvement in H2 2024 as biotech funding conditions improved
- Manufacturing Solutions partially offset DSA/RMS weakness
Gross Margin Compression
- Gross margins declined ~290 bps FY2022→FY2024
- Drivers: (1) fixed cost deleverage from lower DSA volumes; (2) elevated NHP costs in RMS; (3) CGT CDMO scale-up costs before revenue materialized; (4) restructuring-related inefficiencies
- Partially offset by pricing increases and mix shift toward Manufacturing Solutions
Adjusted vs. GAAP Divergence
CRL carries substantial acquisition intangibles (~$2.3B gross, ~$1.4B net as of FY2023) from decades of M&A. Amortization is $140–160M/year, creating a persistent gap between GAAP and adjusted earnings. Restructuring charges further widened this gap in FY2023–FY2024 ($100–150M in non-recurring charges).
Restructuring Impact
The "Fit for Purpose" restructuring program (announced mid-2023):
- ~$200M+ in pre-tax charges over 2023–2024
- ~3,400 headcount reductions (~13%)
- Facility closures/consolidations in North America and Europe
- Annual run-rate savings targeted at ~$150–200M; expected to benefit FY2025 margins
Segment Profitability (Approximate, FY2023)
| Segment | Revenue | Operating Margin (Adj.) |
|---|---|---|
| RMS | $813M | ~22–24% |
| DSA | $2,379M | ~18–20% |
| Manufacturing | $680M | ~15–18% |
| Corporate/Unallocated | — | (~$130M) |
Manufacturing Solutions margins impacted by CGT CDMO ramp-up losses in 2022–2023.
Below-the-Line Items
| Item | FY2022 | FY2023 |
|---|---|---|
| Interest Expense | ~$108M | ~$145M |
| Effective Tax Rate (adj.) | ~23% | ~22% |
| Minority Interest | ~$20M | ~$15M |
Rising interest expense reflects higher rates on floating-rate debt (CRL has a mix of term loans and revolving credit).
Consensus Estimates (FY2025E–FY2026E)
| Metric | FY2025E | FY2026E |
|---|---|---|
| Revenue | ~$3,900M | ~$4,100M |
| Adj. EPS | ~$10.80 | ~$12.00 |
| Revenue Growth | ~+3% | ~+5% |
| Adj. EBITDA Margin | ~22–23% | ~23–24% |
Consensus expects a modest recovery as biotech funding normalizes and restructuring savings flow through.
Cash Flow Generation
| Metric | FY2022 | FY2023 |
|---|---|---|
| Operating Cash Flow | ~$680M | ~$575M |
| Capex | ~$340M | ~$290M |
| Free Cash Flow | ~$340M | ~$285M |
| FCF Conversion (adj. net income) | ~57% | ~52% |
FCF conversion has been below historical norms due to elevated capex (CGT facility buildout 2021–2023) and restructuring cash outflows. Management targets improving FCF conversion to ~50–55% normalized as capex normalizes.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $CRL.